Aethlon Medical Releases First Quarter Financial Results and Corporate Updates for 2025

Aethlon Medical, Inc. (Nasdaq: AEMD), a company focused on developing medical therapeutics for cancer and infectious diseases, recently announced its financial outcomes for the first quarter of the fiscal year ending June 30, 2025. The report not only highlights the financial metrics but also provides updates on ongoing clinical trials and operational achievements. In a significant stride forward, Aethlon completed the first treatment cohort in its Australian hematological trial, with impressive results showing no severe device-related adverse events.

During the first quarter, Aethlon reported that all participants in the initial cohort of the Hemopurifier® cancer trial were treated successfully without any serious complications. This trial involves patients with solid tumors that have failed to respond to traditional anti-PD-1 immunotherapy. The fact that the safety review board recommended advancing to the next cohort speaks volumes about the promising potential of the Hemopurifier device. The updated trial protocol now allows for a broader patient eligibility, incorporating treatment regimens that utilize anti-PD-1 agents like Pembrolizumab and Nivolumab.

In addition to the success in Australian trials, Aethlon reported significant operational efficiencies, achieving a 31.6% reduction in operating expenses. The company highlighted these figures as a sign of its commitment to resource allocation towards generating critical clinical data. With the remaining cash balance of approximately $3.8 million at the end of the fiscal quarter, Aethlon is well-positioned to advance its initiatives, including the second cohort of the Hemopurifier trial scheduled to commence shortly.

Aethlon's preclinical studies have also revealed promising data concerning the Hemopurifier's ability to eliminate platelet-derived extracellular vesicles (EVs). With a reported 98.5% efficacy in removing these EVs in a simulated treatment, the Hemopurifier demonstrates the potential to improve therapeutic responses for patients resistant to existing treatments. Such findings hold significant implications for ongoing clinical research and potential expansions into broader therapeutic areas, particularly concerning diseases associated with elevated levels of EVs.

As part of its commitment to addressing the Long COVID syndrome, Aethlon presented findings at the Keystone Symposium, suggesting the Hemopurifier may also have applications beyond oncology, targeting post-acute sequelae stemming from COVID-19 infections. The collaboration with UCSF aims to explore the effectiveness of the Hemopurifier in patients suffering from Long COVID, a condition impacting millions with persistent symptoms.

The company plans to host a conference call today at 4:30 p.m. ET to discuss its financial results further and provide in-depth insights into the developments and strategic direction moving forward. Interested parties can register for the call, indicating Aethlon's commitment to transparency and communication with investors and stakeholders alike.

Summary of Financial Outcomes

For the quarter ended June 30, 2025, Aethlon reported consolidated operating expenses of approximately $1.8 million compared to $2.6 million for the same period in 2024, an overall reduction primarily driven by leaner payroll expenses and lower professional fees. The reduced operational costs, coupled with ongoing research success, underline Aethlon's proactive approach in a challenging financial environment.

Looking ahead, Aethlon Medical remains committed to driving innovative solutions through its Hemopurifier technology, aiming for full regulatory approval and broader clinical applications in oncology and beyond. Stakeholders and interested parties should continue monitoring the company's progress as it navigates the complexities of drug development within the oncology and infectious disease landscapes.